Research Article
Th1 and Th2 Immune Response in Chronic Hepatitis B Patients during a Long-Term Treatment with Adefovir Dipivoxil
Table 3
Th1/Th2 cytokines producing CD3+CD4+ cells in patients.
| | TW | IL-2% CD3+CD4+ | IFN-γ% CD3+CD4+ | TNF-α% CD3+CD4+ | IL-4% CD3+CD4+ | IL-10% CD3+CD4+ |
| | TW0 | 0.6 (0–7.0) | 0.4 (0–9.4) | 0.7 (0.1–14.3) | 0.4 (0–6.0) | 0.6 (0–3.8) | | TW12 | 3.9 (0.2–27.6) | 3.0 (0.1–48.5) | 8.6 (0.5–42.0) | 6.6 (0.4–16.3) | 6.5 (0.3–38.7) | | TW24 | 11.6 (1.6–37) | 22.5 (0.0–47.9) | 24.7 (4.1–76.1) | 17.2 (2.2–41.7) | 21.0 (7.9–58.1) | | TW36 | 14.7 (1.7–70.6) | 7.4 (1.3–31.4) | 22.9 (2.6–73.9) | 5.9 (1.2–35.7) | 19.7 (2.1–74.5) | | TW52 | 11.4 (1.7–36.5) | 19.6 (0.4–53.3) | 15.5 (0.6–47.0) | 34.4 (2.9–52.3) | 9.6 (1.7–35.7) | | TW65 | 10.2 (6.2–27.9) | 12.5 (8.5–28.5) | 8.1 (5.7–21.6) | 32.9 (9.4–42.9) | 7.7 (2.4–14.4) | | TW78 | 7.6 (4.2–17.2) | 9.8 (6.4–15.0) | 14.9 (3.2–39.9) | 13.6 (7.1–32.4) | 9.7 (4.2–38.2) | | TW92 | 14.0 (6.0–26.7) | 11.9 (6.6–23.0) | 26.2 (12.7–42.6) | 21.1 (9.8–33.3) | 12.0 (4.2–29.4) | | TW104 | 7.4 (4.6–35.3) | 14.2 (5.7–27.1) | 10.8 (6.2–36.2) | 10.6 (6.2–19.6) | 9.4 (5.6–17.2) |
|
|
*The data were expressed as median % and range.
value for all treatment were statistically different from TW0 <.05.
|
